Valuation: Celsion Corporation

Market Cap 68.49L 59.3L 55.42L 50.65L 95.45L 65Cr 96.95L 6.5Cr 2.55Cr 33Cr 2.57Cr 2.52Cr 108.85Cr P/E 2026 *
-0.48x
P/E 2027 * -0.72x
Enterprise Value 68.49L 59.3L 55.42L 50.65L 95.45L 65Cr 96.95L 6.5Cr 2.55Cr 33Cr 2.57Cr 2.52Cr 108.85Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%+24.68%+76.72%+103.05% 7.09TCr
-2.35%+2.88%+35.39%+64.72% 5.54TCr
-0.34%+36.23%+19.17%+499.78% 2.94TCr
-0.30%+18.51%+56.61%+4.86% 2.41TCr
-0.64%+0.82%-15.71%-13.86% 2.33TCr
+0.05%+6.12%+46.81%-21.81% 1.84TCr
+9.77%+25.32%+252.40%+442.16% 1.7TCr
0.00%+10.84%+31.14%+628.97% 1.61TCr
-1.44%-6.53%+39.92%+143.24% 1.31TCr
Average +0.44%+390.71%+60.27%+205.68% 2.97TCr
Weighted average by Cap. -0.25%+349.16%+56.53%+166.25%

Financials

2026 *2027 *
Net sales - -
Net income -1.64Cr -1.42Cr -1.33Cr -1.21Cr -2.29Cr -156.49Cr -2.32Cr -16Cr -6.11Cr -78Cr -6.16Cr -6.03Cr -260.74Cr -2.33Cr -2.02Cr -1.89Cr -1.73Cr -3.25Cr -222.48Cr -3.3Cr -22Cr -8.69Cr -111.3Cr -8.76Cr -8.57Cr -370.7Cr
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-